Compare TotalEnergies SE (TTE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs Zimmer Biomet Holdings Inc — how do they compare? TotalEnergies SE trades at $87.78 (market cap $191.82B), while Zimmer Biomet Holdings Inc trades at $89.6 (market cap $16.95B). The key difference: TotalEnergies SE is far larger — about 11.3× Zimmer Biomet Holdings Inc's market cap, and TotalEnergies SE pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold TotalEnergies SE for 90 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TTE | ZBH | |
|---|---|---|
Market Cap | $191.82B | $16.95B |
Volume | 3,311,339 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $93.60 | $103.98 |
52-Week Low | $57.39 | $79.58 |
Typical Hold Time | 90 Days | 89 Days |
Enterprise Value | $222.81B | $24.02B |
Dividend Yield | 4.93% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but recent earnings beats in Q1 and Q2 2026. The stock trades at attractive valuations with a P/E of 10.77 and P/S of 0.96, supported by a 9.08% net income margin. Recent news highlights a $10 billion investment plan in Argentina and a strategic focus on boosting cash flow and dividends through 2030.
The outlook is positive given analyst consensus targets of $95.33 and strong buy ratings (55.88%), though risks include declining revenue trends from 2022-2025 and exposure to oil price volatility. The company's shareholder returns via dividends and buybacks provide support, but investors should monitor execution of growth initiatives amid energy market uncertainties.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
